DekaBank Deutsche Girozentrale Invests $700,000 in Iovance Biotherapeutics (IOVA) Stock


DekaBank Deutsche Girozentrale purchased a new position in Iovance Biotherapeutics (NASDAQ:IOVA) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 42,400 shares of the biotechnology company’s stock, valued at approximately $700,000.


A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. BlackRock Inc. grew its position in Iovance Biotherapeutics by 9.0% in the fourth quarter. BlackRock Inc. now owns 4,864,841 shares of the biotechnology company’s stock worth $38,918,000 after acquiring an additional 401,743 shares in the last quarter. Perceptive Advisors LLC grew its position in Iovance Biotherapeutics by 1.1% in the fourth quarter. Perceptive Advisors LLC now owns 4,776,114 shares of the biotechnology company’s stock worth $38,208,000 after acquiring an additional 50,000 shares in the last quarter. Farallon Capital Management LLC grew its position in Iovance Biotherapeutics by 119.6% in the fourth quarter. Farallon Capital Management LLC now owns 1,866,900 shares of the biotechnology company’s stock worth $14,935,000 after acquiring an additional 1,016,900 shares in the last quarter. QVT Financial LP grew its position in Iovance Biotherapeutics by 70.1% in the fourth quarter. QVT Financial LP now owns 1,124,295 shares of the biotechnology company’s stock worth $8,615,000 after acquiring an additional 463,486 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Iovance Biotherapeutics by 9.4% in the fourth quarter. Geode Capital Management LLC now owns 574,043 shares of the biotechnology company’s stock worth $4,592,000 after acquiring an additional 49,151 shares in the last quarter. Institutional investors own 64.85% of the company’s stock.


Get Iovance Biotherapeutics alerts:

Shares of Iovance Biotherapeutics opened at $16.95 on Monday, Marketbeat Ratings reports. Iovance Biotherapeutics has a 1 year low of $4.45 and a 1 year high of $19.90. The company has a market cap of $1.52 billion, a price-to-earnings ratio of -12.02 and a beta of 5.94.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its earnings results on Thursday, May 10th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.02). equities research analysts forecast that Iovance Biotherapeutics will post -1.27 EPS for the current fiscal year.


Several research analysts recently commented on the company. Wells Fargo reiterated a “buy” rating and issued a $23.00 price target on shares of Iovance Biotherapeutics in a research report on Monday, January 29th. B. Riley restated a “buy” rating and set a $18.00 target price on shares of Iovance Biotherapeutics in a research report on Thursday, January 25th. Chardan Capital restated a “buy” rating on shares of Iovance Biotherapeutics in a research report on Monday, January 22nd. HC Wainwright restated a “buy” rating and set a $22.00 target price on shares of Iovance Biotherapeutics in a research report on Friday, May 11th. Finally, BidaskClub lowered Iovance Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, April 4th. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $20.81.


Iovance Biotherapeutics Profile

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.

Want to see what other hedge funds are holding IOVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iovance Biotherapeutics (NASDAQ:IOVA).

Institutional Ownership by Quarter for Iovance Biotherapeutics (NASDAQ:IOVA)

Leave a Reply

Your email address will not be published. Required fields are marked *